ロード中...
Japan’s Special Approval for Emergency System During the COVID‐19 Pandemic
The development of drugs for coronavirus disease 2019 (COVID‐19) is a global challenge. In Japan, remdesivir was approved in May 2020 for COVID‐19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. In February 2021, a vaccine against COVID‐19 was approved. These tw...
保存先:
| 出版年: | Clin Pharmacol Ther |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8239700/ https://ncbi.nlm.nih.gov/pubmed/34032279 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.2310 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|